实体瘤中PDL1扩增的患病率及免疫检查点阻断的初步反应
在9例接受PD-1/PD-L1阻断治疗的患者中,6例(66.7%)获得客观缓解,中位无进展生存期为15.2个月。研究提示PDL1扩增可作为部分实体瘤对检查点阻断反应的生物标志物。
要点
- PDL1扩增在实体瘤中总体患病率为0.7%,见于100多种肿瘤类型。
- 多数PDL1扩增肿瘤(84.8%)具有低至中等肿瘤突变负荷。
- 9例PDL1扩增患者接受检查点阻断后,6例(66.7%)客观缓解,中位PFS 15.2个月。
核心结论
- PDL1扩增在实体瘤中发生率低(0.7%),但部分PDL1扩增患者对PD-1/PD-L1阻断有客观反应。
主要发现
- 84.8%的PDL1扩增肿瘤为低至中等TMB。
- PDL1扩增与免疫组化PD-L1高表达不总是一致。
- 9例PDL1扩增实体瘤患者接受检查点阻断后,6例(66.7%)客观缓解,中位PFS为15.2个月。
关键数值与推荐
- 客观缓解者包括胶质母细胞瘤1例(PFS≥5.2个月)、头颈鳞癌2例(PFS≥9和15.2个月)、转移性基底细胞癌2例(PFS 3.8和≥24.1个月)、尿路上皮癌1例(PFS≥17.8个月)。
临床怎么用
- 对部分实体瘤患者,PDL1扩增可能作为PD-1/PD-L1阻断反应的潜在生物标志物,尤其在不伴MSI、PD-L1高表达或高TMB时仍需考虑。
局限性
- 回顾性设计,治疗患者样本量小(9例),需大规模前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Copy number alterations in programmed cell death ligand 1 (PDL1 or CD274), programmed cell death 1 ligand 2 (PDCD1LG2 or PDL2), and Janus kinase 2 (JAK2) genes (chromosome 9p24.1) characterize Hodgkin lymphoma, resulting in high response rates to programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade. The prevalence and utility of PDL1 amplification as a response biomarker to PD-1/PD-L1 blockade are unknown in other tumors. OBJECTIVES: To examine the prevalence of PDL1 amplification and its utility as a response biomarker to PD-1/PD-L1 blockade in solid tumors. DESIGN, SETTING, AND PARTICIPANTS: This retrospective study (October 1, 2012, to October 1, 2017) used a deidentified tumor database from a commercial company and annotated clinical records from a subset of patients treated at a university tertiary referral center. The study analyzed 118 187 tumors from the deidentified database, including a clinically annotated subgroup of 2039 malignant tumors. INTERVENTIONS: Comprehensive genomic profiling was performed on all samples to determine PDL1 amplification, microsatellite instability, and tumor mutational burden (TMB). A subset of patients was treated with PD-1/PD-L1 blockade. MAIN OUTCOMES AND MEASURES: The prevalence of PDL1 amplification was determined among 118 187 patient samples that underwent next-generation sequencing. Solid tumors treated with checkpoint blockade were evaluated for response and progression-free survival (PFS). RESULTS: Of the 118 187 deidentified tumor samples, PDL1 amplifications were identified in 843 (0.7%), including more than 100 types of solid tumors. Most PDL1-amplified tumors (84.8%) had a low to intermediate TMB. PDL1 amplification did not always correlate with high-positive PD-L1 expression by immunohistochemical analysis. Six of 9 patients (66.7%) from 1 center with PDL1-amplified solid tumors had objective responses after checkpoint blockade administration. The median PFS among all treated patients was 15.2 months. Responders included 1 patient with glioblastoma (PFS, ≥5.2 months), 2 patients with head and neck squamous cell cancer (PFS, ≥9 and 15.2 months), 2 patients with metastatic basal cell cancer (PFS, 3.8 and ≥24.1 months), and 1 patient with urothelial cancer (PFS, ≥17.8 months). CONCLUSIONS AND RELEVANCE: The results of this study suggest that PDL1 amplification occurs in a small subset of malignant tumors. Additional large-scale, prospective studies of PDL1-amplified cancers are warranted to confirm the responses to checkpoint blockade described herein, even in the absence of microsatellite instability, high PD-L1 expression, and a high TMB.
引用
- Goodman AM, Piccioni D, Kato S, et al. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018. PMID: 29902298. doi:10.1001/jamaoncol.2018.1701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。